SecBot SecBot
PRESS-RELEASE ·Filed Jun 15, 2026

PHVS

Pharvaris N.V.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The RAPIDe-3 data significantly de-risks the on-demand NDA filing expected in H1 2026. The CHAPTER-3 prophylaxis readout in Q3 2026 is the next major catalyst. Traders should monitor for FDA acceptance of the NDA and any advisory committee meeting dates. The strong efficacy and safety profile positions deucrictibant as a potential oral alternative to injectable standard-of-care, which could capture meaningful market share in the ~$4B+ HAE market.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.54
T+0 close · Jun 15, 2026 · via day close
Latest settled
+19.66%
T+60 · $37.74
Vs SPY
+18.65%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $31.54entry
  2. T+1 · 5mo ago −0.25%α +0.34% · $31.46
  3. T+5 · 5mo ago +4.63%α +6.01% · $33.00
  4. T+20 · 4mo ago +11.19%α +11.94% · $35.07
  5. T+60 · 2mo ago +19.66%α +18.65% · $37.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris presented positive Phase 3 RAPIDe-3 data at EAACI 2026, showing deucrictibant achieved a median time to onset of symptom relief of 1.28 hours vs >12 hours for placebo, and median time to complete resolution of 11.95 hours vs >48 hours. The majority of attacks (83.0%) were treated with a single capsule, and 93.2% required no rescue medication. Long-term prophylaxis data from CHAPTER-1 OLE showed ~92% reduction in attack rates and 100% of participants reporting well-controlled disease. The company is preparing NDA submission for on-demand treatment and expects topline data from the pivotal CHAPTER-3 prophylaxis study in Q3 2026.

Key Facts

  • RAPIDe-3 Phase 3: median time to onset of symptom relief 1.28 hours (deucrictibant) vs >12 hours (placebo)
  • Median time to complete resolution: 11.95 hours (deucrictibant) vs >48 hours (placebo)
  • 83.0% of attacks treated with a single capsule; 93.2% required no rescue medication
  • CHAPTER-1 OLE: ~92% reduction in HAE attack rates; ~50% of participants attack-free during entire extension
  • 100% of participants reported well-controlled disease during long-term prophylaxis (Week 62 to end of study)
  • Integrated CV safety analysis (~570 participants): no QT prolongation, no serious arrhythmias, no sudden cardiac death
  • NDA submission for on-demand deucrictibant planned for first half of 2026; CHAPTER-3 topline data expected Q3 2026
  • Deucrictibant has orphan drug designation from FDA, European Commission, and Swissmedic

Financial Impact

No financial figures provided; clinical-stage company with no approved products or revenue. Positive Phase 3 data supports regulatory filing and potential market entry in HAE (multi-billion dollar market).

pipeline valueregulatory probabilitymarket access

Risk Factors

  • Regulatory risk: FDA may require additional data or issue a Complete Response Letter despite positive Phase 3 results
  • Competition: Takeda's Takhzyro (injectable), BioCryst's Orladeyo (oral prophylactic), and Ionis/Arrowhead's pipeline candidates
  • Commercialization risk: Pharvaris has no commercial infrastructure; may need partnership or significant investment
  • Manufacturing and supply chain risk for oral formulations
  • Clinical risk: CHAPTER-3 prophylaxis study results not yet available; could differ from Phase 2 OLE data

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3311646

Track record

51 reports on PHVS

Performance horizon

14 of 17 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026